Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: B cell receptor signaling pathway (mmu04662)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
1500003O
03Rik
KLA  ATP  ATP+KLA
 NM_019769 RIKEN cDNA 1500003O03 gene (1500003O03Rik), mRNA [NM_019769] KLA .92 .89 .89 .86 .85 .92 1.08
ATP 1.01 1.16 1.16 1.53 1.70 3.33 2.09
KLA/ATP .89 .97 .93 1.17 1.19 2.86 2.57
2010110P
09Rik
KLA  ATP  ATP+KLA
 NM_027363 RIKEN cDNA 2010110P09 gene (2010110P09Rik), mRNA [NM_027363] KLA .99 .98 1.02 .99 .94 1.01 1.01
ATP 1.04 1.05 .97 1.05 .95 .98 .95
KLA/ATP .93 1.00 1.02 .97 1.01 .96 .97
AK036998
KLA  ATP  ATP+KLA
 AK036998 adult female vagina cDNA, RIKEN full-length enriched library, clone:9930034M05 product:unclassifiable, full insert sequence. [AK036998] KLA 1.43 1.09 .89 .79 .96 .97 .71
ATP 1.04 1.04 .71 .64 .90 .82 .82
KLA/ATP 1.34 1.23 1.01 .89 1.10 .82 .75
Akt1
KLA  ATP  ATP+KLA
 NM_009652 thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] KLA .80 .80 .75 .75 .71 .70 .82
ATP 1.00 1.02 .76 .85 .76 .68 .84
KLA/ATP .82 .80 .64 .68 .67 .61 .72
Akt2
KLA  ATP  ATP+KLA
 NM_007434 thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] KLA 1.45 1.49 1.81 1.61 1.83 1.17 .92
ATP 1.12 1.12 1.00 1.28 1.20 .94 1.06
KLA/ATP 1.48 1.70 1.69 1.58 1.57 1.32 1.27
Akt3
KLA  ATP  ATP+KLA
 NM_011785 thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] KLA 3.42 3.45 5.31 5.16 4.65 3.80 2.12
ATP 1.12 1.22 1.10 1.37 1.02 1.11 1.56
KLA/ATP 3.72 4.17 4.62 4.64 2.74 2.05 3.82
BB113440
KLA  ATP  ATP+KLA
 BB113440 gb|BB113440 RIKEN full-length enriched, adult male urinary bladder Mus musculus cDNA clone 9530041B19 3. [BB113440] KLA .94 .95 .94 .95 1.05 .99 1.05
ATP 1.03 1.07 1.79 1.71 1.51 1.12 1.06
KLA/ATP .95 1.11 1.27 1.15 1.05 1.14 1.25
Bcl10
KLA  ATP  ATP+KLA
 AK080820 adult male corpora quadrigemina cDNA, RIKEN full-length enriched library, clone:B230313B18 product:unclassifiable, full insert sequence [AK080820] KLA 1.44 1.52 1.23 1.38 1.54 1.25 1.08
ATP 1.31 1.35 1.59 1.40 3.05 2.29 .90
KLA/ATP 1.58 2.14 1.93 1.47 2.94 1.95 1.33
Bcl10
KLA  ATP  ATP+KLA
 NM_009740 B-cell leukemia/lymphoma 10 (Bcl10), mRNA [NM_009740] KLA 1.63 1.57 1.42 1.42 1.52 1.04 1.14
ATP 1.10 1.12 1.04 1.06 1.97 2.63 1.15
KLA/ATP 1.40 1.58 1.36 1.27 1.54 1.87 1.51
Blnk
KLA  ATP  ATP+KLA
 NM_008528 B-cell linker (Blnk), mRNA [NM_008528] KLA 1.53 1.39 1.23 1.31 1.01 1.41 1.21
ATP .95 .81 1.09 .87 2.09 1.28 .97
KLA/ATP 1.21 1.23 1.44 1.00 2.09 1.88 1.39
Btk
KLA  ATP  ATP+KLA
 NM_013482 Bruton agammaglobulinemia tyrosine kinase (Btk), mRNA [NM_013482] KLA 1.10 1.24 1.01 1.33 1.07 1.27 1.01
ATP .95 1.05 .86 .97 .66 .72 .82
KLA/ATP 1.14 1.35 1.12 1.52 .96 .70 .82
Card11
KLA  ATP  ATP+KLA
 AK002346 adult male kidney cDNA, RIKEN full-length enriched library, clone:0610008L17 product:CASPASE RECRUITMENT DOMAIN PROTEIN 11 (CARD-CONTAINING MAGUK PROTEIN 3) (CARMA 1) homolog [Homo sapiens], full insert sequence. [AK002346] KLA .83 .86 .89 .91 1.13 .99 .99
ATP .97 .93 .89 .93 .88 .89 .98
KLA/ATP .91 .87 .89 .86 .88 .92 1.01
Card11
KLA  ATP  ATP+KLA
 NM_175362 caspase recruitment domain family, member 11 (Card11), mRNA [NM_175362] KLA .33 .29 .31 .44 .71 1.30 1.45
ATP .84 .68 .79 .71 .38 .26 .47
KLA/ATP .33 .27 .40 .35 .38 .37 .85
Cd19
KLA  ATP  ATP+KLA
 NM_009844 CD19 antigen (Cd19), mRNA [NM_009844] KLA 1.05 1.04 1.09 1.05 1.03 1.07 1.10
ATP 1.04 1.03 .99 1.07 .93 .97 .97
KLA/ATP 1.04 1.03 1.02 .97 1.01 1.00 1.08
Cd22
KLA  ATP  ATP+KLA
 NM_009845 CD22 antigen (Cd22), transcript variant 2, mRNA [NM_009845] KLA .89 .90 .89 .90 .93 1.16 1.81
ATP 1.02 1.06 1.03 1.15 .96 .88 2.26
KLA/ATP .94 .92 .90 .97 .86 .90 1.15
Cd72
KLA  ATP  ATP+KLA
 NM_007654 CD72 antigen (Cd72), transcript variant 2, mRNA [NM_007654] KLA .79 .90 .95 1.03 1.87 3.02 2.79
ATP 1.04 1.07 .96 1.13 .96 .59 2.73
KLA/ATP .92 .86 .86 .96 .93 1.24 3.77
Cd79a
KLA  ATP  ATP+KLA
 NM_007655 CD79A antigen (immunoglobulin-associated alpha) (Cd79a), mRNA [NM_007655] KLA .96 1.05 .97 1.07 .97 1.05 .93
ATP .98 1.05 1.02 1.30 1.05 1.11 .96
KLA/ATP .97 1.00 1.08 1.12 1.06 1.06 1.04
Cd79b
KLA  ATP  ATP+KLA
 NM_008339 CD79B antigen (Cd79b), mRNA [NM_008339] KLA .78 .79 .72 .67 .60 .56 .61
ATP 1.00 1.09 1.11 2.45 3.90 .92 .31
KLA/ATP .81 .77 .73 1.03 1.25 1.02 .23
Cd81
KLA  ATP  ATP+KLA
 NM_133655 CD 81 antigen (Cd81), mRNA [NM_133655] KLA .80 .79 .78 .74 .59 .45 .25
ATP .89 .74 .63 .54 .45 .57 .47
KLA/ATP .75 .67 .65 .51 .45 .39 .41
Chuk
KLA  ATP  ATP+KLA
 NM_007700 conserved helix-loop-helix ubiquitous kinase (Chuk), mRNA [NM_007700] KLA 1.32 1.42 1.41 1.17 1.32 1.22 1.40
ATP 1.22 1.30 1.18 .97 1.02 1.00 1.37
KLA/ATP 1.56 1.61 1.21 1.09 .83 .84 1.17
Cr2
KLA  ATP  ATP+KLA
 NM_007758 complement receptor 2 (Cr2), mRNA [NM_007758] KLA .98 .98 .99 1.01 1.00 .99 1.02
ATP 1.03 .99 .94 1.01 1.02 .95 .99
KLA/ATP 1.04 1.07 1.07 1.08 1.06 1.04 .93
Dapp1
KLA  ATP  ATP+KLA
 AK079794 0 day neonate thymus cDNA, RIKEN full-length enriched library, clone:A430068J17 product:dual adaptor for phosphotyrosine and 3-phosphoinositides 1, full insert sequence. [AK079794] KLA 1.02 .99 .98 1.08 .98 1.04 1.04
ATP 1.09 .97 .91 1.00 1.01 .93 .95
KLA/ATP .99 .92 1.11 .99 .98 1.01 1.04
Dapp1
KLA  ATP  ATP+KLA
 NM_011932 dual adaptor for phosphotyrosine and 3-phosphoinositides 1 (Dapp1), mRNA [NM_011932] KLA 1.13 1.15 1.12 1.21 1.36 2.08 1.30
ATP 1.00 1.00 .98 .92 .61 .93 1.42
KLA/ATP 1.15 1.09 1.17 1.03 .88 1.16 2.50
EG629860
KLA  ATP  ATP+KLA
 M17953 gb|Mouse Ig rearranged H-chain V-region mRNA VJ1 [M17953] KLA .96 1.05 1.03 1.08 1.08 1.02 .98
ATP .97 .99 1.05 1.10 .95 .94 .91
KLA/ATP .96 .94 .97 1.04 .97 1.01 .89
Fcgr2b
KLA  ATP  ATP+KLA
 NM_001077189 Fc receptor, IgG, low affinity IIb (Fcgr2b), transcript variant 1, mRNA [NM_001077189] KLA 16.93 17.57 21.75 27.43 34.13 31.88 5.70
ATP 1.11 1.09 1.17 1.46 2.81 11.26 1.92
KLA/ATP 16.51 17.91 23.67 29.22 22.67 25.33 9.54
Fcgr2b
KLA  ATP  ATP+KLA
 NM_010187 Fc receptor, IgG, low affinity IIb (Fcgr2b), transcript variant 2, mRNA [NM_010187] KLA 11.41 11.67 14.06 15.47 17.28 18.63 4.69
ATP 1.05 1.06 1.18 1.57 2.27 8.97 2.10
KLA/ATP 10.98 12.01 15.03 18.38 15.15 16.00 8.33
Fos
KLA  ATP  ATP+KLA
 NM_010234 FBJ osteosarcoma oncogene (Fos), mRNA [NM_010234] KLA .42 .33 .64 .61 .71 .85 .71
ATP 3.48 5.46 23.78 25.22 1.71 2.36 1.50
KLA/ATP .90 1.74 5.97 8.62 1.28 2.42 4.52
Grb2
KLA  ATP  ATP+KLA
 NM_008163 growth factor receptor bound protein 2 (Grb2), mRNA [NM_008163] KLA .92 .88 .90 1.27 1.43 1.22 1.00
ATP 1.02 .83 .51 .42 .92 .70 .57
KLA/ATP .84 .77 .61 .56 1.56 1.49 .52
Grb2
KLA  ATP  ATP+KLA
 U07617 Grb2 adaptor protein (grb2) mRNA, complete cds. [U07617] KLA .83 .80 .95 1.13 1.38 1.36 1.06
ATP .84 .74 .51 .41 .82 .74 .59
KLA/ATP .77 .70 .57 .54 1.49 1.39 .53
Gsk3b
KLA  ATP  ATP+KLA
 NM_019827 glycogen synthase kinase 3 beta (Gsk3b), mRNA [NM_019827] KLA 1.06 1.03 1.11 1.01 1.26 1.28 1.26
ATP 1.18 1.27 1.15 2.07 2.37 2.32 1.67
KLA/ATP 1.15 1.21 .98 1.50 1.67 2.50 2.99
Hras1
KLA  ATP  ATP+KLA
 NM_008284 Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] KLA .79 .82 .77 .82 .94 1.03 1.07
ATP 1.01 .95 .69 .83 .79 1.12 1.15
KLA/ATP .84 .77 .61 .65 .82 1.00 1.05
Ifitm1
KLA  ATP  ATP+KLA
 NM_026820 interferon induced transmembrane protein 1 (Ifitm1), transcript variant 1, mRNA [NM_026820] KLA 3.21 3.65 4.41 4.70 5.89 5.30 2.15
ATP .95 .93 1.76 5.07 5.54 4.21 5.93
KLA/ATP 3.48 4.21 7.14 11.28 11.28 7.56 8.17
Igh-VJ55
8
KLA  ATP  ATP+KLA
 AY547436 immunoglobulin heavy chain VDJ region mRNA, partial cds [AY547436] KLA 1.06 1.05 1.01 .93 1.03 .96 .93
ATP .99 1.00 1.06 .95 .96 1.06 1.05
KLA/ATP .98 .94 1.07 .95 .97 .99 1.02
Igh-VJ55
8
KLA  ATP  ATP+KLA
 CA578712 gb|K0727F04-5N NIA Mouse Hematopoietic Stem Cell (Lin- [CA578712] KLA .99 .94 1.01 1.10 .93 .97 .92
ATP .93 1.04 1.01 .98 1.05 .96 .95
KLA/ATP .99 .95 .95 .98 1.02 .98 .95
Igh-VJ55
8
KLA  ATP  ATP+KLA
 ENSMUST00000103412 ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE_DB;Acc:IGHA] [ENSMUST00000103412] KLA 1.01 .97 1.20 1.01 .98 1.44 1.24
ATP .99 .98 1.07 1.03 1.00 1.01 1.21
KLA/ATP .99 1.02 .96 1.03 .97 1.13 1.30
Igh-VJ55
8
KLA  ATP  ATP+KLA
 ENSMUST00000103413 ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE_DB;Acc:IGHE] [ENSMUST00000103413] KLA 1.00 .99 1.06 1.06 .99 1.03 1.02
ATP 1.08 1.06 1.06 1.06 1.02 1.06 .95
KLA/ATP 1.00 1.04 1.09 1.02 1.06 1.02 .95
Igh-VJ55
8
KLA  ATP  ATP+KLA
 U39781 J558+ IgM heavy chain mRNA, hybridoma clone ME2B7, partial cds. [U39781] KLA .93 .89 .98 .97 1.03 1.00 .94
ATP 1.04 1.02 1.08 .94 .93 .90 .79
KLA/ATP .88 .89 .97 .93 .88 .92 .82
Ikbkb
KLA  ATP  ATP+KLA
 NM_010546 inhibitor of kappaB kinase beta (Ikbkb), mRNA [NM_010546] KLA 1.88 2.10 2.14 1.83 1.73 1.31 1.19
ATP .81 .74 .55 .49 .59 1.05 .96
KLA/ATP 1.86 1.73 1.39 1.12 .89 1.17 1.24
Ikbkg
KLA  ATP  ATP+KLA
 AK042138 3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630062P04 product:unclassifiable, full insert sequence. [AK042138] KLA .92 .87 .78 .78 .87 .88 .62
ATP .84 .71 .80 .50 1.15 2.33 .61
KLA/ATP .72 .69 .74 .48 1.06 1.97 .68
Ikbkg
KLA  ATP  ATP+KLA
 NM_010547 inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 1, mRNA [NM_010547] KLA 1.51 1.63 1.74 1.83 1.83 1.73 1.72
ATP .80 .79 .82 .75 .66 2.58 2.37
KLA/ATP 1.43 1.42 1.17 1.04 .71 1.54 3.17
Ikbkg
KLA  ATP  ATP+KLA
 NM_178590 inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 2, mRNA [NM_178590] KLA .84 .93 .86 .91 1.03 .89 .88
ATP 1.03 .98 .68 .56 .51 .93 .68
KLA/ATP .89 .81 .55 .52 .41 .67 .65
Inpp5d
KLA  ATP  ATP+KLA
 NM_010566 inositol polyphosphate-5-phosphatase D (Inpp5d), transcript variant 1, mRNA [NM_010566] KLA .17 .15 .13 .20 .56 1.17 .81
ATP 1.09 1.05 .86 .70 .37 .42 1.25
KLA/ATP .18 .15 .14 .12 .17 .37 1.19
Inppl1
KLA  ATP  ATP+KLA
 NM_010567 inositol polyphosphate phosphatase-like 1 (Inppl1), transcript variant 1, mRNA [NM_010567] KLA .82 .80 .73 .81 .79 .72 .94
ATP 1.05 1.04 .69 .58 .56 .87 .98
KLA/ATP .90 .83 .58 .46 .87 1.07 1.34
Jun
KLA  ATP  ATP+KLA
 NM_010591 Jun oncogene (Jun), mRNA [NM_010591] KLA 1.08 .96 1.09 1.09 .75 .88 .81
ATP 1.26 1.48 4.45 8.73 4.02 1.16 1.99
KLA/ATP 1.12 1.38 3.52 5.17 3.32 .49 1.42
Kras
KLA  ATP  ATP+KLA
 NM_021284 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] KLA .53 .49 .40 .42 .49 .95 1.05
ATP .98 1.01 1.16 1.17 1.39 1.29 1.74
KLA/ATP .50 .47 .50 .56 1.00 1.24 1.58
Lilrb3
KLA  ATP  ATP+KLA
 NM_011095 leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 3 (Lilrb3), mRNA [NM_011095] KLA 1.72 1.76 1.91 2.57 2.60 2.82 2.30
ATP .95 .85 .82 .58 .78 1.38 1.77
KLA/ATP 1.49 1.42 1.52 1.10 1.16 1.39 2.84
Lyn
KLA  ATP  ATP+KLA
 NM_010747 Yamaguchi sarcoma viral (v-yes-1) oncogene homolog (Lyn), transcript variant 2, mRNA [NM_010747] KLA 2.48 2.80 3.76 3.81 5.30 4.57 2.46
ATP 1.06 1.18 .82 .97 .74 1.45 1.21
KLA/ATP 2.82 3.16 2.24 2.87 1.73 1.80 2.63
Malt1
KLA  ATP  ATP+KLA
 AK172081 activated spleen cDNA, RIKEN full-length enriched library, clone:F830035G05 product:unclassifiable, full insert sequence [AK172081] KLA 8.85 8.52 6.90 6.44 8.01 3.16 3.02
ATP 1.37 1.55 2.57 6.23 6.73 5.82 1.27
KLA/ATP 9.01 10.69 14.85 12.51 4.33 4.50 6.89
Malt1
KLA  ATP  ATP+KLA
 NM_172833 mucosa associated lymphoid tissue lymphoma translocation gene 1 (Malt1), mRNA [NM_172833] KLA 17.74 16.14 15.00 9.66 9.87 4.22 3.54
ATP 1.20 1.19 2.20 5.12 10.20 8.16 1.25
KLA/ATP 19.07 18.41 21.75 20.07 13.32 7.72 8.40
Map2k1
KLA  ATP  ATP+KLA
 NM_008927 mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] KLA 1.82 2.00 2.31 2.03 2.51 2.20 1.51
ATP .99 1.14 .81 .87 .90 1.57 1.11
KLA/ATP 1.90 2.03 1.50 1.93 1.63 2.03 2.06
Map2k2
KLA  ATP  ATP+KLA
 NM_023138 mitogen-activated protein kinase kinase 2 (Map2k2), mRNA [NM_023138] KLA .96 1.01 1.09 .99 1.11 1.15 1.42
ATP 1.07 1.05 .74 .86 1.04 1.16 1.21
KLA/ATP 1.14 1.03 .68 .78 .85 1.01 1.20
Mapk1
KLA  ATP  ATP+KLA
 NM_001038663 mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] KLA .97 1.03 .93 .86 .79 1.01 1.04
ATP .96 1.18 1.01 1.13 .84 1.04 1.16
KLA/ATP .99 .99 .84 .87 .63 .96 1.26
Mapk1
KLA  ATP  ATP+KLA
 NM_011949 mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] KLA .88 .80 .80 .73 .75 .76 .65
ATP .97 .96 1.06 .88 .90 .68 .48
KLA/ATP .82 .81 .78 .65 .64 .64 .45
Mapk3
KLA  ATP  ATP+KLA
 NM_011952 mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] KLA .81 .85 .88 .72 .79 .73 .90
ATP 1.13 1.30 .92 1.48 1.08 .68 1.03
KLA/ATP 1.01 1.01 .66 1.13 .77 .77 1.16
Mm.1355
KLA  ATP  ATP+KLA
 142386539 Unknown KLA .98 1.05 .92 .96 .94 1.02 1.00
ATP 1.01 .99 1.02 1.34 1.15 1.01 1.09
KLA/ATP 1.03 1.02 .93 1.05 1.09 1.00 1.02
Mm.21312
8
KLA  ATP  ATP+KLA
 141801344 Unknown KLA .96 .95 .83 .77 .52 .99 1.32
ATP .80 .82 1.09 .80 .83 1.19 1.46
KLA/ATP .78 .92 .98 .62 .71 .94 1.41
Mm.25381
9
KLA  ATP  ATP+KLA
 118130676 Unknown KLA 1.81 1.88 1.96 1.62 1.89 2.44 1.56
ATP .92 .91 1.24 1.01 1.16 2.06 1.95
KLA/ATP 1.62 1.86 1.86 1.41 1.89 2.37 1.97
Mm.33138
9
KLA  ATP  ATP+KLA
 158508469 Unknown KLA .80 .79 .81 .82 .72 .64 .50
ATP .95 .85 .56 .48 .30 .33 .46
KLA/ATP .71 .64 .50 .41 .33 .32 .42
Nfat5
KLA  ATP  ATP+KLA
 AK172011 activated spleen cDNA, RIKEN full-length enriched library, clone:F830029B05 product:nuclear factor of activated T-cells 5, full insert sequence. [AK172011] KLA .94 .90 .93 .93 1.28 1.27 1.16
ATP .95 .76 1.13 1.27 1.93 2.21 1.18
KLA/ATP .85 .84 1.10 .92 1.53 1.63 1.66
Nfat5
KLA  ATP  ATP+KLA
 NM_018823 nuclear factor of activated T-cells 5 (Nfat5), transcript variant b, mRNA [NM_018823] KLA .95 1.01 .99 1.03 1.08 1.13 1.19
ATP 1.05 1.22 1.67 1.98 1.74 1.38 1.17
KLA/ATP 1.03 1.07 1.34 1.38 1.30 1.19 1.40
Nfat5
KLA  ATP  ATP+KLA
 NM_133957 nuclear factor of activated T-cells 5 (Nfat5), transcript variant a, mRNA [NM_133957] KLA 1.07 1.07 1.00 .96 1.42 1.36 1.51
ATP 1.15 1.19 1.81 4.36 6.34 3.49 1.12
KLA/ATP 1.27 1.08 1.87 2.72 3.58 3.05 2.07
Nfatc1
KLA  ATP  ATP+KLA
 NM_016791 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (Nfatc1), transcript variant 1, mRNA [NM_016791] KLA .71 .66 .68 .62 .63 .67 .81
ATP 1.12 1.29 1.15 1.21 .83 .63 1.25
KLA/ATP .78 .79 .65 .74 .59 .45 .92
Nfatc1
KLA  ATP  ATP+KLA
 NM_198429 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (Nfatc1), transcript variant 2, mRNA [NM_198429] KLA .49 .41 .50 .43 .50 .78 .69
ATP 1.05 .81 .84 .54 .60 .38 .69
KLA/ATP .46 .37 .45 .32 .62 .39 .61
Nfatc2
KLA  ATP  ATP+KLA
 AK081853 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130082H17 product:nuclear factor of activated T-cells, cytoplasmic 2, full insert sequence. [AK081853] KLA .56 .52 .59 .61 .78 .78 .66
ATP 1.19 1.27 .67 .65 .62 .53 .79
KLA/ATP .52 .49 .71 .57 .65 .52 .53
Nfatc2
KLA  ATP  ATP+KLA
 NM_001037177 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 (Nfatc2), transcript variant 2, mRNA [NM_001037177] KLA .84 .79 .74 .82 .89 .98 .80
ATP 1.06 1.13 1.01 .87 .86 .83 1.10
KLA/ATP .76 .72 .89 .84 .84 .81 .84
Nfatc2
KLA  ATP  ATP+KLA
 NM_010899 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 (Nfatc2), transcript variant 1, mRNA [NM_010899] KLA .90 .91 .86 .91 .86 1.07 1.00
ATP 1.08 1.11 1.45 1.04 .88 .85 1.18
KLA/ATP .85 .89 .92 .89 .93 .84 1.13
Nfatc3
KLA  ATP  ATP+KLA
 AK084848 13 days embryo lung cDNA, RIKEN full-length enriched library, clone:D430001G08 product:nuclear factor of activated T-cells, cytoplasmic 3, full insert sequence. [AK084848] KLA 1.08 .96 .98 1.00 .98 1.03 .98
ATP 1.00 1.03 .93 .92 .92 1.11 .98
KLA/ATP 1.01 .87 1.10 .97 .96 .96 .99
Nfatc3
KLA  ATP  ATP+KLA
 NM_010901 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 (Nfatc3), mRNA [NM_010901] KLA .77 .68 .67 .77 .85 .90 1.04
ATP 1.01 .95 .89 .70 .70 .92 .98
KLA/ATP .77 .66 .64 .59 .82 .90 .90
Nfatc4
KLA  ATP  ATP+KLA
 AK014164 13 days embryo head cDNA, RIKEN full-length enriched library, clone:3110041H08 product:nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4, full insert sequence. [AK014164] KLA .90 .92 .91 1.00 .99 .98 .95
ATP .90 1.03 .96 .98 .95 .97 1.00
KLA/ATP .95 .87 1.00 .98 .96 .96 .92
Nfatc4
KLA  ATP  ATP+KLA
 NM_023699 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 (Nfatc4), mRNA [NM_023699] KLA 1.28 1.38 1.44 1.58 1.40 1.41 1.46
ATP 1.03 1.06 1.23 1.24 1.32 1.40 1.41
KLA/ATP 1.30 1.38 1.47 1.28 1.38 1.40 1.63
Nfkb1
KLA  ATP  ATP+KLA
 BC050841 nuclear factor of kappa light chain gene enhancer in B-cells 1, p105, mRNA (cDNA clone IMAGE:6392793), complete cds. [BC050841] KLA 5.81 4.96 4.77 3.21 3.37 2.00 1.71
ATP 1.39 1.52 3.25 12.63 13.64 4.80 1.08
KLA/ATP 7.21 8.69 19.53 23.93 11.70 2.85 2.01
Nfkb1
KLA  ATP  ATP+KLA
 M57999 gb|Mouse transcription factor NF-kappa-B DNA binding subunit mRNA, complete cds. [M57999] KLA 8.55 7.87 7.35 6.13 3.51 1.85 1.38
ATP .98 .96 1.21 3.06 5.29 4.67 .69
KLA/ATP 7.32 7.20 8.71 10.82 5.55 2.77 1.54
Nfkbia
KLA  ATP  ATP+KLA
 NM_010907 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (Nfkbia), mRNA [NM_010907] KLA 18.65 18.46 13.63 17.88 14.25 9.17 7.92
ATP .91 1.09 7.11 32.39 17.44 10.49 1.72
KLA/ATP 15.57 17.66 15.73 23.91 13.83 10.73 9.48
Nfkbib
KLA  ATP  ATP+KLA
 NM_010908 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta (Nfkbib), mRNA [NM_010908] KLA 4.63 4.69 4.36 4.27 4.23 2.52 2.17
ATP 1.11 1.22 1.55 4.23 4.93 3.66 1.76
KLA/ATP 4.71 5.41 4.58 7.08 6.20 4.73 4.11
Nfkbie
KLA  ATP  ATP+KLA
 NM_008690 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon (Nfkbie), mRNA [NM_008690] KLA 5.87 5.26 4.28 4.30 4.38 3.56 2.69
ATP .92 1.04 1.55 1.83 3.57 8.04 2.35
KLA/ATP 5.07 5.19 5.86 4.34 3.56 8.64 9.00
Nras
KLA  ATP  ATP+KLA
 NM_010937 neuroblastoma ras oncogene (Nras), mRNA [NM_010937] KLA 1.20 1.22 1.27 1.20 1.09 .91 .84
ATP .98 .91 .69 .61 .59 .67 .78
KLA/ATP 1.22 1.14 .97 .79 .73 .61 .72
Pik3ap1
KLA  ATP  ATP+KLA
 AK171021 NOD-derived CD11c +ve dendritic cells cDNA, RIKEN full-length enriched library, clone:F630218N05 product:phosphoinositide-3-kinase adaptor protein 1, full insert sequence [AK171021] KLA 1.50 1.68 2.02 1.89 2.34 2.36 2.67
ATP 1.08 1.14 .70 .73 .70 .68 2.56
KLA/ATP 1.78 1.63 .94 1.38 .94 1.40 3.40
Pik3ap1
KLA  ATP  ATP+KLA
 NM_031376 phosphoinositide-3-kinase adaptor protein 1 (Pik3ap1), mRNA [NM_031376] KLA 1.95 1.92 2.40 2.59 3.05 2.56 2.75
ATP 1.18 1.21 .79 1.07 .98 1.00 2.68
KLA/ATP 2.18 2.33 1.85 2.35 1.31 1.87 4.82
Pik3ca
KLA  ATP  ATP+KLA
 ENSMUST00000108243 ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] KLA 1.07 1.01 .91 .90 .98 .96 .86
ATP 1.03 .87 1.12 .63 1.22 1.86 .60
KLA/ATP 1.05 .82 .91 .61 1.17 1.26 .63
Pik3ca
KLA  ATP  ATP+KLA
 NM_008839 phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] KLA 1.15 1.11 1.05 .82 .99 1.03 1.27
ATP .98 1.00 .79 .75 .96 1.32 1.10
KLA/ATP 1.10 .98 .64 .72 .80 1.20 1.41
Pik3cb
KLA  ATP  ATP+KLA
 NM_029094 phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] KLA 1.06 1.06 1.03 .73 .68 .98 1.69
ATP 1.04 1.21 .95 1.02 .85 .93 1.73
KLA/ATP 1.15 1.27 .73 .83 .58 .81 1.81
Pik3cd
KLA  ATP  ATP+KLA
 NM_008840 phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] KLA 2.28 2.42 3.10 4.17 3.35 2.31 1.34
ATP 1.02 .91 .99 .63 .30 .67 .80
KLA/ATP 2.14 2.23 2.70 1.51 1.17 .85 .72
Pik3cd
KLA  ATP  ATP+KLA
 U86587 phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] KLA 2.21 2.24 3.71 3.17 3.67 2.66 1.48
ATP 1.00 1.03 .93 .96 .46 .75 .97
KLA/ATP 2.27 2.32 1.97 2.02 1.01 .99 .98
Pik3cg
KLA  ATP  ATP+KLA
 NM_020272 phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] KLA .53 .53 .61 .64 .97 .86 .79
ATP 1.01 1.13 .88 .89 .52 .53 .53
KLA/ATP .58 .53 .43 .60 .40 .43 .62
Pik3r1
KLA  ATP  ATP+KLA
 NM_001077495 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] KLA 1.05 1.07 1.03 1.00 1.01 1.20 .85
ATP .97 1.02 1.48 1.42 1.76 1.33 1.23
KLA/ATP 1.11 1.12 1.06 1.17 1.24 .99 1.12
Pik3r2
KLA  ATP  ATP+KLA
 NM_008841 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] KLA .50 .50 .48 .43 .46 .66 .75
ATP .78 .68 .45 .43 .28 .57 1.37
KLA/ATP .49 .38 .32 .33 .38 .67 1.10
Pik3r3
KLA  ATP  ATP+KLA
 NM_181585 phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] KLA 1.59 1.49 1.37 1.17 1.05 1.55 1.41
ATP 1.12 1.00 1.33 1.70 2.01 2.37 2.02
KLA/ATP 1.63 1.54 1.58 1.70 2.43 2.68 1.92
Pik3r5
KLA  ATP  ATP+KLA
 NM_177320 phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] KLA 3.57 3.58 4.16 3.54 4.11 2.59 2.39
ATP 1.08 1.08 .93 1.67 3.11 1.88 1.34
KLA/ATP 3.91 3.70 3.30 3.80 2.70 2.04 3.00
Plcg2
KLA  ATP  ATP+KLA
 NM_172285 phospholipase C, gamma 2 (Plcg2), mRNA [NM_172285] KLA .76 .74 .68 .66 .71 .92 .95
ATP .96 .90 .95 .87 .81 .79 .91
KLA/ATP .76 .71 .69 .62 .72 .78 .68
Ppp3ca
KLA  ATP  ATP+KLA
 NM_008913 protein phosphatase 3, catalytic subunit, alpha isoform (Ppp3ca), mRNA [NM_008913] KLA .76 .85 .81 .85 .73 .70 .52
ATP .96 .78 .55 .46 .31 .33 .48
KLA/ATP .74 .64 .52 .42 .37 .36 .45
Ppp3cb
KLA  ATP  ATP+KLA
 AK135203 12 days embryo male wolffian duct includes surrounding region cDNA, RIKEN full-length enriched library, clone:6720421K10 product:protein phosphatase 3, catalytic subunit, beta isoform, full insert sequence. [AK135203] KLA 1.74 1.57 1.91 1.59 1.47 1.26 1.40
ATP 1.17 1.03 1.30 1.00 .81 .62 1.37
KLA/ATP 1.68 1.70 1.91 1.37 1.09 .47 1.13
Ppp3cb
KLA  ATP  ATP+KLA
 AK171904 activated spleen cDNA, RIKEN full-length enriched library, clone:F830018L06 product:Protein phosphatase 3 catalytic subunit beta3 (EC 3.1.3.16) (Serine [AK171904] KLA 1.29 1.29 1.21 1.15 1.22 1.13 1.28
ATP .90 .86 .80 .98 .94 .73 .92
KLA/ATP 1.06 1.03 .77 1.04 .92 .68 .90
Ppp3cb
KLA  ATP  ATP+KLA
 NM_008914 protein phosphatase 3, catalytic subunit, beta isoform (Ppp3cb), mRNA [NM_008914] KLA 1.21 1.29 1.38 1.24 1.29 1.08 1.23
ATP 1.15 1.31 1.09 1.29 .86 .60 .64
KLA/ATP 1.33 1.40 1.04 1.28 .79 .58 .73
Ppp3cc
KLA  ATP  ATP+KLA
 AK037563 16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130026K22 product:unclassifiable, full insert sequence [AK037563] KLA 1.27 1.18 1.21 1.15 1.01 .92 1.36
ATP .96 1.09 1.10 1.03 .85 1.06 1.47
KLA/ATP 1.17 1.24 1.07 1.13 .91 .88 1.36
Ppp3cc
KLA  ATP  ATP+KLA
 NM_008915 protein phosphatase 3, catalytic subunit, gamma isoform (Ppp3cc), mRNA [NM_008915] KLA 1.64 1.81 1.79 1.35 .90 .70 1.31
ATP .90 .90 1.13 .93 .86 1.40 1.60
KLA/ATP 1.45 1.62 1.74 1.47 1.04 1.01 1.31
Ppp3r1
KLA  ATP  ATP+KLA
 NM_024459 protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type I) (Ppp3r1), mRNA [NM_024459] KLA 1.02 1.17 .93 1.27 1.15 1.30 1.30
ATP .97 .95 .77 .91 .99 1.18 1.10
KLA/ATP 1.12 1.04 .88 1.00 1.10 1.10 1.07
Ppp3r2
KLA  ATP  ATP+KLA
 NM_001004025 protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type II) (Ppp3r2), mRNA [NM_001004025] KLA 1.03 1.05 1.06 1.08 1.12 1.05 1.04
ATP 1.00 1.02 1.04 1.04 .99 .99 1.01
KLA/ATP 1.04 1.12 1.03 1.09 1.00 .99 1.00
Prkcb1
KLA  ATP  ATP+KLA
 NM_008855 protein kinase C, beta 1 (Prkcb1), mRNA [NM_008855] KLA .92 .95 .93 .78 .77 1.08 1.83
ATP 1.03 1.12 1.09 1.23 .90 2.08 .96
KLA/ATP .98 .99 .82 .89 .62 1.01 1.08
Ptpn6
KLA  ATP  ATP+KLA
 NM_001077705 protein tyrosine phosphatase, non-receptor type 6 (Ptpn6), transcript variant 2, mRNA [NM_001077705] KLA .87 .90 1.03 1.05 1.83 1.96 2.34
ATP 1.06 1.09 .94 1.08 .51 .34 1.04
KLA/ATP .98 .93 .71 .95 .67 .64 1.44
Ptpn6
KLA  ATP  ATP+KLA
 NM_013545 protein tyrosine phosphatase, non-receptor type 6 (Ptpn6), transcript variant 1, mRNA [NM_013545] KLA 1.24 1.20 1.46 1.42 2.43 2.27 2.10
ATP 1.18 1.20 1.10 1.49 .80 .58 1.09
KLA/ATP 1.36 1.42 1.27 1.66 1.12 .87 1.46
Ptpn6
KLA  ATP  ATP+KLA
 S63763 gb|me/Hcph (mev)=viable motheaten/hematopoietic cell protein-tyrosine phosphatase {insertion} [mice, mRNA Partial Mutant, 120 nt]. [S63763] KLA 1.06 1.03 1.12 1.14 1.11 1.01 1.09
ATP 1.03 .97 .96 .90 .89 1.17 1.76
KLA/ATP 1.07 1.00 1.03 .98 1.00 1.29 1.44
Rac1
KLA  ATP  ATP+KLA
 NM_009007 RAS-related C3 botulinum substrate 1 (Rac1), mRNA [NM_009007] KLA 1.02 1.01 1.02 .99 1.03 1.15 1.08
ATP .99 1.15 1.01 1.27 1.06 1.20 1.06
KLA/ATP 1.00 1.04 .88 1.16 .91 1.21 1.38
Rac2
KLA  ATP  ATP+KLA
 NM_009008 RAS-related C3 botulinum substrate 2 (Rac2), mRNA [NM_009008] KLA 1.55 1.68 1.86 2.15 3.36 3.59 3.74
ATP 1.13 1.16 .74 .99 .84 .91 1.66
KLA/ATP 1.59 1.71 1.19 1.56 1.21 1.60 3.48
Rac3
KLA  ATP  ATP+KLA
 NM_133223 RAS-related C3 botulinum substrate 3 (Rac3), mRNA [NM_133223] KLA 2.03 2.20 2.64 2.18 2.95 2.29 1.41
ATP 1.02 1.12 .94 1.42 1.16 .84 .87
KLA/ATP 2.30 2.32 1.57 2.55 1.75 1.47 1.61
Raf1
KLA  ATP  ATP+KLA
 AK036317 16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] KLA 1.47 1.34 1.55 1.29 1.59 1.32 1.46
ATP 1.05 .98 .54 .63 3.32 2.07 1.01
KLA/ATP 1.57 1.33 .79 .96 2.26 1.38 1.35
Raf1
KLA  ATP  ATP+KLA
 NM_029780 v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] KLA 1.65 1.64 1.93 1.77 1.77 1.72 1.81
ATP .95 .96 .83 .80 2.22 2.92 1.19
KLA/ATP 1.68 1.64 1.39 1.32 1.85 2.50 2.06
Rasgrp3
KLA  ATP  ATP+KLA
 NM_207246 RAS, guanyl releasing protein 3 (Rasgrp3), mRNA [NM_207246] KLA .13 .11 .11 .12 .10 .07 .05
ATP .82 .71 1.08 .69 .32 .09 .12
KLA/ATP .12 .12 .17 .16 .15 .09 .08
Rela
KLA  ATP  ATP+KLA
 NM_009045 v-rel reticuloendotheliosis viral oncogene homolog A (avian) (Rela), mRNA [NM_009045] KLA 2.05 2.05 2.07 1.75 1.83 1.58 1.33
ATP 1.03 1.08 1.10 1.44 1.61 2.48 1.05
KLA/ATP 2.17 2.27 2.05 2.47 1.93 2.35 2.02
Sos1
KLA  ATP  ATP+KLA
 NM_009231 Son of sevenless homolog 1 (Drosophila) (Sos1), mRNA [NM_009231] KLA 2.36 2.40 3.42 3.15 2.78 1.81 1.71
ATP .99 1.00 .99 1.15 1.14 1.25 1.24
KLA/ATP 2.41 2.26 1.95 2.44 1.47 1.66 1.37
Sos2
KLA  ATP  ATP+KLA
 XM_127051 gb|PREDICTED: Mus musculus Son of sevenless homolog 2 (Drosophila) (Sos2), mRNA [XM_127051] KLA .81 .77 .79 .92 1.04 1.06 1.20
ATP 1.00 1.00 1.09 .79 .68 .81 .94
KLA/ATP .77 .69 .71 .60 .64 .77 1.07
Syk
KLA  ATP  ATP+KLA
 NM_011518 spleen tyrosine kinase (Syk), mRNA [NM_011518] KLA 2.48 2.59 2.57 2.26 3.29 3.75 3.19
ATP .96 .85 .59 1.01 2.80 3.77 2.11
KLA/ATP 2.56 2.09 1.16 1.35 2.50 4.33 5.10
Vav1
KLA  ATP  ATP+KLA
 NM_011691 vav 1 oncogene (Vav1), mRNA [NM_011691] KLA .79 .83 .98 1.17 1.97 2.42 2.26
ATP 1.06 1.02 .88 1.01 1.34 .82 1.36
KLA/ATP .88 .85 .73 .78 1.25 1.47 2.17
Vav2
KLA  ATP  ATP+KLA
 BC053060 vav 2 oncogene, mRNA (cDNA clone MGC:62363 IMAGE:5704852), complete cds [BC053060] KLA .73 .58 .55 1.16 .76 1.35 1.75
ATP .99 .89 .79 .82 .67 .85 1.09
KLA/ATP .64 .63 .61 .65 .66 .80 1.23
Vav2
KLA  ATP  ATP+KLA
 NM_009500 vav 2 oncogene (Vav2), mRNA [NM_009500] KLA .98 1.05 .98 .99 1.02 1.36 1.43
ATP 1.07 1.06 .96 1.01 .89 .95 1.08
KLA/ATP 1.04 1.05 .98 1.03 .88 .99 1.13
Vav3
KLA  ATP  ATP+KLA
 NM_020505 vav 3 oncogene (Vav3), transcript variant 1, mRNA [NM_020505] KLA .95 .94 .86 .87 .82 .66 .56
ATP 1.06 1.09 .81 1.05 .80 .75 .85
KLA/ATP 1.00 .84 .62 .85 .74 .56 .74